OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Asciminib as a new option in the treatment of chronic myeloid leukemia
Betül İbiş, Mario Tiribelli, Ahmet Emre Eşkazan
Future Oncology (2021) Vol. 17, Iss. 36, pp. 5003-5005
Closed Access | Times Cited: 9
Betül İbiş, Mario Tiribelli, Ahmet Emre Eşkazan
Future Oncology (2021) Vol. 17, Iss. 36, pp. 5003-5005
Closed Access | Times Cited: 9
Showing 9 citing articles:
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
Zehra Narlı Özdemir, Necati Alp Kılıçaslan, Musa Yılmaz, et al.
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 3-15
Open Access | Times Cited: 31
Zehra Narlı Özdemir, Necati Alp Kılıçaslan, Musa Yılmaz, et al.
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 3-15
Open Access | Times Cited: 31
Patient‐reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!
Ahmet Emre Eşkazan
Cancer (2025) Vol. 131, Iss. 3
Closed Access
Ahmet Emre Eşkazan
Cancer (2025) Vol. 131, Iss. 3
Closed Access
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
Deniz Özmen, Duygu Demet Alpaydın, Muhammed Ali Saldoğan, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 4, pp. 411-423
Closed Access | Times Cited: 2
Deniz Özmen, Duygu Demet Alpaydın, Muhammed Ali Saldoğan, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 4, pp. 411-423
Closed Access | Times Cited: 2
Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
Qingya Cui, Peiqi Liang, Haiping Dai, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Qingya Cui, Peiqi Liang, Haiping Dai, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial
Jorge E. Cortés, Andreas Hochhaus, Naoto Takahashi, et al.
Future Oncology (2022) Vol. 18, Iss. 38, pp. 4161-4170
Open Access | Times Cited: 8
Jorge E. Cortés, Andreas Hochhaus, Naoto Takahashi, et al.
Future Oncology (2022) Vol. 18, Iss. 38, pp. 4161-4170
Open Access | Times Cited: 8
Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib
Zhijing Liu, Dongzhi Wu, Chengjie Ke, et al.
Oncology (2024), pp. 1-13
Closed Access | Times Cited: 1
Zhijing Liu, Dongzhi Wu, Chengjie Ke, et al.
Oncology (2024), pp. 1-13
Closed Access | Times Cited: 1
Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting
Ahmet Emre Eşkazan, Rıdvan Ali, Ebru Alnıgeniş, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 2, pp. 97-106
Closed Access | Times Cited: 5
Ahmet Emre Eşkazan, Rıdvan Ali, Ebru Alnıgeniş, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 2, pp. 97-106
Closed Access | Times Cited: 5
Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting
Reyhan Yılmaz, Ahmet Emre Eşkazan
Future Oncology (2023) Vol. 19, Iss. 8, pp. 545-547
Closed Access | Times Cited: 1
Reyhan Yılmaz, Ahmet Emre Eşkazan
Future Oncology (2023) Vol. 19, Iss. 8, pp. 545-547
Closed Access | Times Cited: 1
MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE
Sameen Shahid, Muhammad Farooq Sabar, Zafar Iqbal, et al.
International Journal of Pharmacy & Integrated Health Sciences (2023) Vol. 5, Iss. 1
Open Access
Sameen Shahid, Muhammad Farooq Sabar, Zafar Iqbal, et al.
International Journal of Pharmacy & Integrated Health Sciences (2023) Vol. 5, Iss. 1
Open Access
